AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04274101 — intervention group
Intervention type: BEHAVIORAL
Intervention: Adverse events
Description: Adverse events in patients treated with Nifurtimox and Benznidazole
Study NCT02884089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT03333707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacifica App
Description: The app contains several activities which are digital implementations of standard psychotherapy practices. Users may select which app elements they would like to use, and when. These app elements include relaxation and meditation activities, tools to examine your thoughts or self-talk, goal setting lists, and mood and health ratings. The app also has a peer support community where users can communicate with others who are having similar experiences. There is no minimum requirement for amount of time spent on any given activity, or in the app in total. The commercially available app has a feature to connect users to their existing healthcare providers, but this feature will not be available to study participants. Study participants may continue to see their existing providers.
Study NCT00554788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo peripheral blood stem cell or bone marrow transplant
Study NCT01633788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263 0.1%
Description: 1 drop of AGN-195263 0.1% instilled in each eye twice daily.
Study NCT01633788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263 0.03%
Description: 1 drop of AGN-195263 0.03% instilled in each eye twice daily.
Study NCT00554788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood stem cell or bone marrow transplant
Study NCT01633788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263 0.01%
Description: 1 drop of AGN-195263 0.01% instilled in each eye twice daily.
Study NCT01633788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-195263 Vehicle
Description: 1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
Study NCT00554788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00554788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02754921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous dilatational tracheostomy using Ultra-Perc
Description: Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
Study NCT02754921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
Description: Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
Study NCT02399709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Study NCT02399709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00760682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
Study NCT03857100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audit and feedback - letter and report
Description: letter describing project and report of participants' outlier status and how participants compare to peers
Study NCT04374461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.
Study NCT04374461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood
Description: A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
Study NCT00554788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06376578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Exercise training will progress incrementally, increasing the duration of exercise on the treadmill by 5 minutes every 2 weeks whereby the final duration on the treadmill will be 35 minutes and the total duration will map onto recommended guidelines of 150 minutes per week. Throughout the 8-weeks, the duration of exercise on the cycle ergometer will remain at 15 minutes. Exercise intensity will progress throughout the 8-week intervention on both the treadmill and the cycle ergometer by 5% every 2 weeks, whereby exercise during the final week will be at 70% VO2max.
Study NCT06376578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polar A380 wristwatch physical activity tracker
Description: The research team will monitor individual exercise training weekly using virtual/electronic methods and a 30 minute telephone call. The researcher will provide feedback about how the participant's activity compares to physical activity recommendations, and encouragement and support will be provided verbally.
Study NCT02297386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] DIHYDRO-TESTOSTERONE
Study NCT00554788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00554788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00554788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell or bone marrow transplant
Study NCT00554788 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy
Study NCT00554788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT00554788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02297386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan
Study NCT00617266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tobacco cessation intervention
Description: Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
Study NCT02297386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02297386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study NCT02484755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: See Arm Description
Study NCT01662323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GP's treating HF according the dutch guidelines
Study NCT01934491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training A
Study NCT01934491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training B
Study NCT01806142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides
Description: During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
Study NCT01806142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn oil
Description: During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
Study NCT02611817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC 108 mg
Description: Vedolizumab SC Injection.
Study NCT02611817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vedolizumab placebo-matching SC injection.
Study NCT02611817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab IV 300 mg
Description: Vedolizumab IV Injection.
Study NCT02611817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV 300 mg
Description: Vedolizumab IV Injection.
Study NCT00617266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco cessation intervention
Description: Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
Study NCT00617266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco cessation intervention
Description: Distribution of pamphlets containing information on the hazards of tobacco
Study NCT00617266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco cessation intervention
Description: Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
Study NCT00077766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
Study NCT00077766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or > 80 µg per week, respectively).
Study NCT00721513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00721513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00721513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00721513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00721513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Study NCT00721513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Study NCT00721513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00721513 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00721513 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT00238108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
Study NCT00238108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02843490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
Study NCT01546701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 2 mg sublingual tablet
Study NCT01546701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1 mg/kg IV morphine
Study NCT01108861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN® Endoprosthesis
Description: GORE VIABAHN® Endoprosthesis
Study NCT01108861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain old balloon angioplasty
Description: Plain old balloon angioplasty
Study NCT03988049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1,550 fracionated photothermolysis laser
Description: All subjects will have one side of their face treated with one laser, and the other side with the other laser.
Study NCT03988049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 755 picosecond laser
Description: All subjects will have one side of their face treated with one laser, and the other side with the other laser.
Study NCT03382691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood pressure check
Description: Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
Study NCT04013373 — intervention group
Intervention type: DEVICE
Intervention: SOZO Bioimpedance Spectroscopy Device
Description: Bioimpedance spectroscopy measurements for assessment of fluid status
Study NCT02685306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: 12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
Study NCT02685306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane
Description: 12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
Study NCT00449761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT04401046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later
Description: The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
Study NCT00761085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Standard of care for pain management of acute episode of pain
Study NCT00761085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Compare to standard of care for pain management of acute episode of pain
Study NCT02685306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: 12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
Study NCT06056492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experience of nitrous oxide sedation at assessment
Description: Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
Study NCT06056492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience of nitrous oxide sedation at assessment
Description: Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
Study NCT00068341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
Study NCT00068341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Cycle 1-8 Day 1 or 2 AUC = 6 IV
Study NCT00068341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
Study NCT03530683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
Study NCT03530683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
Study NCT03530683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
Study NCT03530683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
Study NCT03530683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD20 Targeting agent
Description: Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
Study NCT00068341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
Study NCT02857673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Abuse Prevention Problem Solving
Description: The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
Study NCT02857673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
Study NCT01493401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midurethral slings (MUS)
Description: Retropubic, Transobturator, and Single incision MUS can be used.
Study NCT04050618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A test lens
Description: Silicone hydrogel contact lens
Study NCT02209272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bacteriostatic saline
Study NCT02209272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buffered lidocaine
Study NCT03545568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neu5Ac supplementation
Description: Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
Study NCT02476058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Study NCT02476058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Study NCT02476058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Study NCT03882567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro Neuro adaptative Regulator
Description: The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance